What is Auxilius?
Founded in 2020, Auxilius provides a purpose-built platform designed to automate and streamline financial operations for biopharmaceutical companies. The software integrates real-time clinical data, vendor estimates, and site-level invoices to replace manual spreadsheet management with a unified, automated workflow. By consolidating financial data from multiple sources, the platform enables finance and clinical operations teams to improve forecast accuracy, manage trial costs, and ensure compliance with Sarbanes-Oxley requirements. Beyond its technical capabilities, Auxilius differentiates itself by pairing its software with a dedicated operations team of certified public accountants and former auditors, ensuring that clients receive both technological and domain-specific support.
How much funding has Auxilius raised?
Auxilius has raised a total of $20M across 2 funding rounds:
Series A
$10M
Other Financing Round
$10M
Series A (2022): $10M with participation from Renegade Partners, XYZ Venture Capital, and Bain Capital Ventures
Other Financing Round (2024): $10M led by SignalFire
Key Investors in Auxilius
Renegade Partners
A venture capital firm that focuses on backing visionary founders at the early stage, providing high-conviction capital and hands-on partnership to help startups scale into enduring companies.
XYZ Venture Capital
A venture firm that invests in early-stage founders across fintech and enterprise sectors, prioritizing entrepreneurs who possess a key insight and an unfair advantage from deep industry experience.
Bain Capital Ventures
The venture capital division of Bain Capital, managing significant committed capital with a focus on early-stage investments in transformative technology and enterprise software companies.
What's next for Auxilius?
With this major strategic investment, Auxilius is well-positioned to scale its operations and deepen its penetration within the global biopharmaceutical market. The company is expected to leverage this capital to enhance its investigator spend intelligence features and expand its integration capabilities with existing enterprise resource planning and clinical trial management systems. As the firm continues to serve over 65 biopharmaceutical companies, the focus will likely shift toward accelerating product development to meet the increasing demand for automated financial risk management and real-time site payment reconciliation. This strategic expansion will be vital as Auxilius seeks to establish its platform as the industry standard for clinical trial financial planning.
See full Auxilius company page
